Article Information
History
- November 13, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Reetta Virtakoivu1,§,
- Jenna Rannikko1,§,
- Miro Viitala1,§,
- Felix Vaura1,
- Akira Takeda1,
- Tapio Lönnberg2,
- Jussi Koivunen3,
- Panu Jaakkola4,
- Annika Pasanen5,
- Shishir Shetty6,
- Maja de Jonge7,
- Debbie Robbrecht7,
- Yuk Ting Ma6,
- Tanja Skyttä8,
- Anna Minchom9,
- Sirpa Jalkanen1,
- Matti K. Karvonen10,
- Jami Mandelin10,
- Petri Bono11 and
- Maija Hollmén1,*
- 1MediCity Research Laboratory, University of Turku, Turku, Finland
- 2Turku Bioscience Center, University of Turku, Turku, Finland
- 3Oulu University Hospital, MRC Oulu, Oulu, Finland
- 4Department of Oncology and FICAN West Cancer Centre, University of Turku and Turku University Hospital, Finland
- 5Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
- 6Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham; and University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- 7Erasmus MC/Cancer Institute, Rotterdam, the Netherlands
- 8Tampere University Hospital, Tampere, Finland
- 9Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, United Kingdom
- 10Faron Pharmaceuticals, Turku, Finland
- 11Terveystalo Finland and University of Helsinki, Helsinki, Finland
- ↵*Correspondence: Maija Hollmén, Tykistökatu 6A 4th floor, 20520 Turku, Finland; Phone: 00358505142893; Email: maijal{at}utu.fi
↵§ Equal contribution
Posted November 13, 2020.
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors
